Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

ABSTRACT: As a number of epigenetic alterations have been described in cervical cancer which may participate in the development and progression of this tumor, and the primary treatment for locally advanced disease is concurrent chemoradiation, we wanted to evaluate the efficacy and safety of hydralazine and valproate added to radiation and cisplatin. In addition, the transcriptome changes induced by the epigenetic drugs were also evaluated. Keywords: Cervical Cancer, epigenetic therapy, valproate, hydralazine, transcriptional response, epigenetic drugs

ORGANISM(S): Homo sapiens

PROVIDER: GSE8604 | GEO | 2007/07/31

SECONDARY ACCESSION(S): PRJNA101771

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Homo sapiens

Project description:Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

| PRJNA101771 | ENA

Antitumor effects of the hydralazine-valproate combination in lymphoma

Project description:Epigenetic alterations are common in both B cell and T cell lymphomas. These contribute to lymphomagenesis and treatment resistance, hence epigenetic therapy is being investigated. We evaluated the effects of the DNA-methyltrasferase inhibitor hydralazine and the histone deacetylase inhibitor valproate in T-cell lymphoma HuT78 cells and B-cell lymphoma Raji cells.

2021-03-13 | GSE168790 | GEO

Gene Expression Profiles of Epigenetic treatment in primary breast cancer.

Project description:Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine plus the HDAC inhibitor magnesium valproate were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy. Keywords: Epigenetic treatment, Hydralazine, valproate, breast cancer

2006-11-18 | GSE6304 | GEO

Antitumor effects of the hydralazine-valproate combination in lymphoma

Project description:Antitumor effects of the hydralazine-valproate combination in lymphoma

| PRJNA713994 | ENA

Transcription profiling of untreated and cisplatin-based chemoradiation treated human squamous cell carcinomas to improve prediction of outcome after chemoradiation

Project description:Gene expression profiling to predict outcome after chemoradiation in head and neck cancer Purpose. The goal of the present study was to improve prediction of outcome after chemoradiation in advanced head and neck cancer using gene expression analysis. Materials and Methods. We collected 92 biopsies from untreated head and neck cancer patients subsequently given cisplatin-based chemoradiation (RADPLAT) for advanced squamous cell carcinomas (HNSCC). After RNA extraction and labeling we performed dye swap experiments using 35k oligo-microarrays. Supervised analyses were performed to create classifiers to predict local control, locoregional control and disease recurrence. Published gene sets with prognostic value in other studies were also tested. Results. Using supervised classification on the whole series, gene sets separating good and poor outcome could be found for all end-points. However, when splitting tumors into training and validation groups, no robust classifiers could be found. Also previously published signatures with prognostic value have been tested. Conclusion. Gene sets can be found with predictive potential for locoregional control after combined radiation and chemotherapy in HNSCC. How treatment-specific these gene sets are needs further study.

2008-02-19 | E-NCMF-8 | biostudies-arrayexpress

Effect of Sodium Valproate on Rat Primary Hepatocytes.

Project description:This study provides an evaluation of changes in gene expression associated with sodium valproate treatment of rat hepatocytes in vitro. Primary rat hepatocytes were treated for 24 and 48 hours with two doses (500 uM and 10 mM) of sodium valproate and water vehicle control. Five replicates of each treatment were performed. Cells were then extracted and RNA processed for microarray analysis.

2012-08-28 | GSE40338 | GEO

Transcriptional analysis of sodium valproate and lithium in a serotonergic cell line

Project description:Sodium valproate (VPA) and lithium are mood stabilizers, widely prescribed in the treatment of bipolar disorder, and yet the precise modes of therapeutic action for these drugs are not fully understood. After exposure of the rat serotonergic cell line RN46A to VPA, RNA-sequencing (RNA-Seq) analysis showed widespread changes in gene expression but no changes with lithium. Analysis by multiple pipelines revealed that as many as 230 genes were significantly upregulated and 72 genes were significantly downregulated in response to VPA exposure.

2020-03-07 | GSE146493 | GEO

Peripheral circulating mRNA profiling in predicting the pathological response to neoadjuvant chemoradiation for esophageal squamous cell carcinoma

Project description:Analysis of peripheral circulating mRNA expression levels in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma. The hypothesis test was that chemoradiation alters the circulating mRNA expression profiles and the profiling is predictive of pathological response. Results provide information on the response of circulating mRNAs to chemoradiation and identify novel biomarkers or targets in esophageal squamous cell carcinoma. Total RNA obtained from peripheral whole blood before and after neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma. 21 patients with 42 samples were analyzed. The expression profiles from pathological complete responders were compared to non-complete responders.

2014-01-01 | E-GEOD-43519 | biostudies-arrayexpress

Peripheral circulating mRNA profiling in predicting the pathological response to neoadjuvant chemoradiation for esophageal squamous cell carcinoma

2014-01-01 | GSE43519 | GEO

Proteome profiles of primary pancreatic ductal adenocarcinomas undergoing adjuvant chemoradiation link ALDH1A1 to early local recurrence and chemoradiation resistance

Project description:Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with very frequent post-surgical local recurrence. The combination of adjuvant chemotherapy with radiotherapy is under consideration to achieve a prolonged disease-free survival (DFS). To date, few studies have determined protein profiles that are associated with responsiveness to adjuvant chemoradiation. Here, we analyzed the proteomes of primary, surgically resected PDAC tumors subjected to adjuvant chemoradiation and achieving short DFS (median DFS of 6 months, n = 6) or a prolonged DFS (median DFS of 28 months, n = 6) using liquid chromatography tandem mass spectrometry.

2018-09-11 | PXD009254 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data